达沙替尼在异基因造血细胞移植后使用与巨细胞病毒再激活的风险。
Dasatinib Use and Risk of Cytomegalovirus Reactivation After Allogeneic Hematopoietic-Cell Transplantation.
机构信息
Division of Infectious Diseases, Brigham and Women's Hospital.
Division of Medical Oncology, Dana-Farber Cancer Institute.
出版信息
Clin Infect Dis. 2017 Aug 1;65(3):510-513. doi: 10.1093/cid/cix325.
Viral infections have been reported with dasatinib use, but its cytomegalovirus risk after hematopoietic-cell transplantation (HCT) is not known. We found that post-HCT dasatinib use increased the risk of cytomegalovirus reactivation (adjusted hazard ratio, 7.65; 95% confidence interval, 1.84-31.7), controlling for acute graft-versus-host disease, in 109 patients with Philadelphia-chromosome-positive malignancies.
已有报道称达沙替尼的使用与病毒感染相关，但在造血细胞移植（HCT）后使用达沙替尼是否会增加巨细胞病毒再激活的风险尚不清楚。我们发现，在 109 例费城染色体阳性恶性肿瘤患者中，在控制急性移植物抗宿主病的情况下，HCT 后使用达沙替尼会增加巨细胞病毒再激活的风险（调整后的危险比为 7.65；95%置信区间为 1.84-31.7）。
Zotero 插件